Laurion Capital Management LP Editas Medicine, Inc. Transaction History

Laurion Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.67 - $7.28 $82,416 - $128,477	17,648 New	17,648 $82,000
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $5,482 - $8,705	-659 Reduced 0.47%	140,000 $1.24 Million
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $1.71 Million - $2.73 Million	140,659 New	140,659 $1.72 Million
Q3 2020 Nov 13, 2020	SELL	$28.06 - $37.16 $1.02 Million - $1.35 Million	-36,200 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $669,700 - $1.24 Million	36,200 New	36,200 $1.07 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $87.3M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.